Category: Other
PharmaSignal — Other
Neurology, biomanufacturing start-ups bag UK AI funding
Pharmaphorum
The first recipients of the UK government’s 500 million Sovereign AI fund have been announced, including two life sciences-focused start-ups.
221: An Interview With Dutch Neurologist Ewout Groen of SMA Europe
Rare Disease Audio
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Dutch neurologist Ewout Groen, PhD, a member of the Scientific Advisory Board of SMA Europe.
AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
BioPharma Dive
Featured at this year s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and several targeted medicines for lung tumors.
Boehringer Ingelheim launches AI centre in London
Pharmaceutical Technology
The new site will focus on the use of AI models for purposes including the discovery and development of targeted medicines for patients with unmet medical needs.
S16 Ep55: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer
OncLive Podcast
In this podcast, experts Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; and Seth A.
UK Knowledge Quarter welcomes Boehringer Ingelheim AI accelerator
Pharmaphorum
Boehringer Ingelheim has announced expansion of its global Computational Innovation footprint with a new centre dedicated to AI ML in the UK.
What actually drives speed in complex drug development programs
BioPharma Dive
Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.
S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting
OncLive Podcast
In this podcast, experts Barbara Burtness, MD; and Quynh-Thu Le, MD, FACR, FASTRO; discuss recent and ongoing trials and key updates in the management of locally advanced head and neck cancer.
OpenAI introduces GPT-Rosalind, its drug discovery AI
Pharmaphorum
In this week’s second AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, named after UK scientist Rosalind Franklin.
The innovators working to make in vivo cell therapy a reality
Pharmaceutical Technology
As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.
Amazon launches its AI drug discovery platform
Pharmaphorum
Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that combines in silico and wet-lab work in a single application.
Amazon launches AI drug discovery platform
Pharmaceutical Technology
Amazon has already collaborated with Memorial Sloan Kettering Cancer Center with its AI drug discovery software.
Novo Nordisk and OpenAI forge alliance to drive speedy drug development
Pharmaceutical Technology
Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.
220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease
Rare Disease Audio
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Jaime Moore, MD, about weight loss drugs–specifically the role of GLP-1 receptor agonists in treating children with neuromuscula
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Pharmaceutical Technology
Biomarkers are revolutionizing oncology drug development, driving modern precision medicine approaches, targeted clinical trial recruitment strategies, and critical decision-making.
Pulmonary fibrosis drug developer Avalyn files IPO
Pharmaphorum
Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic
BioSpace
Analysts are cautiously optimistic about an IPO rebound for biopharma.
219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy
Rare Disease Audio
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews pediatric psychologist Natalie Truba, PhD, on the psychological aspects of gene therapy in neuromuscular disease.
Aspect Biosystems receives funding for cellular medicine project
Pharmaceutical Business Review
The project will enhance Aspect Biosystems’ clinical development capabilities and bolster its integrated platform for developing and manufacturing advanced cellular medicines.
Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26
Drug Channels
Today’s guest post comes from Chrissy Hand, Chief Product and Commercial Officer at CoverMyMeds.